Check these points
Treat the label as a question to resolve
Federal drug review is handled by the FDA, short for Food and Drug Administration.
As of September 26, 2026, FDA warning letters say research labels do not excuse marketing unapproved products for human treatment.
A warning letter states the agency’s allegations. It is not a court judgment.
Check the exact substance
FDA records checked September 26, 2026 show no US approved product for BPC-157 or ipamorelin.
These are ingredient names found in peptide offers. A familiar name is not evidence of approval.
Ask about claims of new permission
Compounding means a pharmacist or doctor makes or changes a medicine for a patient. A larger business registered with the FDA can also make it.
Individuals or groups requested permission from the FDA to use an ingredient in compounding, then withdrew that request. As of September 26, 2026, taking it back does not mean the FDA approved the ingredient or allowed pharmacies to use it.
Ask for the dated FDA decision that allows the exact product or ingredient to be used. A headline about a withdrawn request does not answer that question.
Notes that explain the checks
One clear federal answer
As of September 26, 2026, the FDA says federal law prohibits compounding retatrutide and cagrilintide.
Those are drug ingredient names. Ask what the service is actually offering if either appears in a treatment plan.
Advice is not a rule change
An FDA advisory panel gives advice; its vote alone cannot change the compounding rules, as of September 26, 2026.
For an approved medicine, ask for the FDA page confirming approval and the approved label. For a pharmacy-made medicine, ask which current rule allows its ingredient to be used. A draft rule or a list of topics for a meeting does not show that permission.